Tanya Lewis Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Tanya Lewis.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Tanya Lewis. Tanya Lewis is a VP Regulatory and Quality in VION PHARMACEUTICALS INC ($VION) and a EVP, Chief Reg. Affairs in Karyopharm Therapeutics Inc. ($KPTI) and a EVP,Chief Reg.&Quality Officer in Karyopharm Therapeutics Inc. ($KPTI) and a Chief Dev. Oper. Off. in Replimune Group, Inc. ($REPL) and a Director in Replimune Group, Inc. ($REPL).
Address: C/O VION PHARMACEUTICALS, INC. 4 SCIENCE PARK NEW HAVEN 06511 CT
Companies in which Tanya Lewis is an Insider
Karyopharm Therapeutics Inc.
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of Tanya Lewis: EVP, Chief Reg. Affairs, EVP,Chief Reg.&Quality Officer
Holdings: 45,401 shares
Current Value: $468,538
Latest Transaction: Mar 01 2021
$KPTI Market Capitalization: $416.55M
$KPTI Previous Close: $10.32
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
Replimune Group, Inc.
Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
Position of Tanya Lewis: Chief Dev. Oper. Off., Director
Holdings: 73,333 shares
Latest Transaction: May 11 2021
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
VION PHARMACEUTICALS INC
Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
Position of Tanya Lewis: VP Regulatory and Quality
Holdings: 20,000 shares
Latest Transaction: Dec 12 2008
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
Latest Insider Trading Transactions of Tanya Lewis
Sentiment: All, KPTI, REPL, VION
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 11 2021 | REPL | Replimune Group, I ... | Lewis Tanya | Chief Dev. Oper. Of ... | Option Exercise | A | 33.99 | 110,000 | 3,738,900 | 110,000 | |
| May 11 2021 | REPL | Replimune Group, I ... | Lewis Tanya | Chief Dev. Oper. Of ... | Grant | A | 0.00 | 73,333 | 0 | 73,333 | 0 to 73.3 K |
| Apr 05 2021 | REPL | Replimune Group, I ... | Lewis Tanya | Director | Option Exercise | A | 31.58 | 16,500 | 521,070 | 16,500 | |
| Mar 01 2021 | KPTI | Karyopharm Therape ... | Lewis Tanya | EVP, Chief Reg. Aff ... | Option Exercise | A | 14.56 | 59,968 | 873,134 | 59,968 | |
| Mar 01 2021 | KPTI | Karyopharm Therape ... | Lewis Tanya | EVP, Chief Reg. Aff ... | Grant | A | 0.00 | 22,013 | 0 | 45,401 | 23.4 K to 45.4 K (+94.12 %) |
| Feb 09 2021 | KPTI | Karyopharm Therape ... | Lewis Tanya | EVP, Chief Reg. Aff ... | Option Exercise | M | 0.00 | 5,650 | 0 | 16,950 | |
| Feb 09 2021 | KPTI | Karyopharm Therape ... | Lewis Tanya | EVP, Chief Reg. Aff ... | Buy | M | 0.00 | 5,650 | 0 | 6,189 | 539 to 6.2 K (+1,048.24 %) |